McLemore, Amy

Eprenetapopt (APR-246) and Azacitidine in TP53 -Mutant Myelodysplastic Syndromes

Sallman, D. A., DeZern, A. E., Garcia-Manero, G., Steensma, D. P., Roboz, G. J., Sekeres, M. A., Cluzeau, T., Sweet, K. L., McLemore, A., McGraw, K. L., et al. (2021) · Journal of Clinical Oncology

Acute Myeloid Leukemia ResearchCancer-related Molecular Pathways

Cited by 465

TP53 mutations in myelodysplastic syndromes and secondary AML confer an immunosuppressive phenotype

Sallman, D. A., McLemore, A. F., Aldrich, A. L., Komrokji, R. S., McGraw, K. L., Dhawan, A., Geyer, S., Hou, H.-A., Eksioglu, E. A., Sullivan, A., et al. (2020) · Blood

Acute Myeloid Leukemia ResearchCancer Immunotherapy and Biomarkers

Cited by 196

Long‐term follow‐up and combined Phase 2 results of eprenetapopt and azacitidine in patients with TP53 mutant MDS/AML

Sallman, D. A., Komrokji, R. S., Dezern, A. E., Sebert, M., Garcia‐Manero, G., Rahmé, R., Winer, E. S., Lehmann‐Che, J., Roboz, G. J., Madelaine, I., et al. (2025) · HemaSphere

Acute Myeloid Leukemia ResearchCancer-related Molecular Pathways

Cited by 26

XPO1 Overexpression Is a Mechanism of Resistance to Eprenetapopt and 5-Azacitidine Therapy That Can be Therapeutically Exploited for the Treatment of TP53 Mutated Myeloid Malignancies

Kruer, T. L., Quintana, A., Ferrall-Fairbanks, M., Zhang, L., Newman, H., McLemore, A. F., Yang, Q., Bencrentsil, N., Komrokji, R. S., Chaudhry, S., et al. (2022) · Blood

Acute Myeloid Leukemia ResearchCancer-related Molecular Pathways

Cited by 8